- Report
- October 2023
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
- Report
- January 2019
- 35 Pages
Global
From €910EUR$1,000USD£780GBP
Fosamax is a drug used to treat musculoskeletal disorders, such as osteoporosis and Paget's disease. It is a bisphosphonate, a type of drug that helps to reduce bone loss and increase bone density. Fosamax is used to prevent and treat osteoporosis in postmenopausal women, as well as to treat Paget's disease in adults. It is also used to treat osteoporosis in men and women who are taking glucocorticoids, a type of steroid medication.
Fosamax is available in both oral and intravenous forms. The oral form is taken once daily, while the intravenous form is administered once every three months. Common side effects of Fosamax include nausea, diarrhea, and abdominal pain.
The Fosamax market is highly competitive, with many companies offering similar products. Some of the major players in the market include Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Other companies in the market include Amgen Inc., Eli Lilly and Company, and GlaxoSmithKline plc. Show Less Read more